Title: | Assessment of a Noninvasive Exhaled Breath Test for the Diagnosis of Oesophagogastric Cancer |
Author(s): | Markar SR; Wiggins T; Antonowicz S; Chin ST; Romano A; Nikolic K; Evans B; Cunningham D; Mughal M; Lagergren J; Hanna GB; |
Address: | "Department Surgery & Cancer, Imperial College London, United Kingdom. Institute of Biomedical Engineering, Imperial College London, United Kingdom. Department of Oncology, Royal Marsden Hospital, London, United Kingdom. Department of Surgery, University College London Hospital, United Kingdom. Department of Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. School of Cancer and Pharmaceutical Sciences, King's College London, United Kingdom" |
DOI: | 10.1001/jamaoncol.2018.0991 |
ISSN/ISBN: | 2374-2445 (Electronic) 2374-2437 (Print) 2374-2437 (Linking) |
Abstract: | "IMPORTANCE: Early esophagogastric cancer (OGC) stage presents with nonspecific symptoms. OBJECTIVE: The aim of this study was to determine the accuracy of a breath test for the diagnosis of OGC in a multicenter validation study. DESIGN, SETTING, AND PARTICIPANTS: Patient recruitment for this diagnostic validation study was conducted at 3 London hospital sites, with breath samples returned to a central laboratory for selected ion flow tube mass spectrometry (SIFT-MS) analysis. Based on a 1:1 cancer:control ratio, and maintaining a sensitivity and specificity of 80%, the sample size required was 325 patients. All patients with cancer were on a curative treatment pathway, and patients were recruited consecutively. Among the 335 patients included; 172 were in the control group and 163 had OGC. INTERVENTIONS: Breath samples were collected using secure 500-mL steel breath bags and analyzed by SIFT-MS. Quality assurance measures included sampling room air, training all researchers in breath sampling, regular instrument calibration, and unambiguous volatile organic compounds (VOCs) identification by gas chromatography mass spectrometry. MAIN OUTCOMES AND MEASURES: The risk of cancer was identified based on a previously generated 5-VOCs model and compared with histopathology-proven diagnosis. RESULTS: Patients in the OGC group were older (median [IQR] age 68 [60-75] vs 55 [41-69] years) and had a greater proportion of men (134 [82.2%]) vs women (81 [47.4%]) compared with the control group. Of the 163 patients with OGC, 123 (69%) had tumor stage T3/4, and 106 (65%) had nodal metastasis on clinical staging. The predictive probabilities generated by this 5-VOCs diagnostic model were used to generate a receiver operator characteristic curve, with good diagnostic accuracy, area under the curve of 0.85. This translated to a sensitivity of 80% and specificity of 81% for the diagnosis of OGC. CONCLUSIONS AND RELEVANCE: This study shows the potential of breath analysis in noninvasive diagnosis of OGC in the clinical setting. The next step is to establish the diagnostic accuracy of the test among the intended population in primary care where the test will be applied" |
Keywords: | Adult Aged Breath Tests/*methods Esophageal Neoplasms/*diagnosis/pathology Female Humans Male Middle Aged Stomach Neoplasms/*diagnosis/pathology; |
Notes: | "MedlineMarkar, Sheraz R Wiggins, Tom Antonowicz, Stefan Chin, Sung-Tong Romano, Andrea Nikolic, Konstantin Evans, Benjamin Cunningham, David Mughal, Muntzer Lagergren, Jesper Hanna, George B eng DRF-2014-07-088/DH_/Department of Health/United Kingdom 2018/05/26 JAMA Oncol. 2018 Jul 1; 4(7):970-976. doi: 10.1001/jamaoncol.2018.0991" |